The overall frequency of the various causes of epithelial tumour of the ovary in this population was similar to those reported in the literature. Ovarian cancer is largely due to benign or pre-malignant conditions. Application of the International Federation of Gynecology and Obstetrics staging system does not provide any advantage over the existing FIGO staging system.
Results from a recent clinical trial suggests that most clinical trials involve only one group of participants. Future clinical trials may need to include more participants to obtain better results. A systematic review of these studies could contribute to the development of future clinical trials.
There was a significant increase regarding the number of new studies published on basic biology, cell biology, genetics, molecular biology, and immunology of carcinoma, ovarian epithelial tumors with respect to a decade ago.
Data from a recent study of this review indicate that there are many possible patterns of cancer treatment combinations. These options vary significantly depending upon the staging and type of tumor.
Carcinoma, ovarian epithelial is rare in the U.S. population, with an incidence rate of about 0.1% per year. This low incidence may reflect a high prevalence of early detection of ovarian malignancy. However, cancer prevention strategies should target high-risk groups such as women with increased BRCA mutation carriership, women with a family history of breast and ovarian cancers, and women over 50 years old.
Survival rate for carcinoma, ovarian epithelial is only 26% at 5 years. The majority of cases of carcinoma, ovarian epithelial were stage III and stage IV at time of diagnosis. Survival rates were lower among patients < 45 years old, whose cancer was not resectable. To decrease the mortality rate for patients with this type of cancer, surgeons should strive to obtain complete surgical resection whenever possible.
Carcinoma of the ovary spreads locally but rarely metastasizes. For early stage disease, the median time interval between diagnosis and death was 2.8 years (range 1.5-6.1 years). The 5 year survival rate was 25%.
The average age at diagnosis for carcinoma, ovarian epithelial was 45 yr, with a range of 31-50 yr. A significant percentage of patients were cleared of cancer after surgery (5%). A majority of cases were diagnosed as early stage (Ia and Ib) carcinoma, ovarian epithelial. A minority of patients had advanced disease at presentation (III and IV). OS was 63+/-11 months, with progressive disease being found in 5% of patients. More than half of all patients had experienced chemotherapy, with 2% receiving platinum-based chemotherapy alone.
The authors conclude that there is no evidence that the risk of major side effects differs between early stage carcinoma and serous borderline tumors. Therefore, an argument against clinical trials can be made on ethical grounds only for early stage carcinomas. However, this remains controversial because of the relatively small number of patients included in trials.
Survivors who participated in the MOB program reported increased self-efficacy, fewer depressive symptoms, and better QoL. Data from a recent study highlight the need for an effective survivorship care model that addresses the emotional needs of survivorship patients.
Findings from a recent study suggest that breast cancer cells may be sensitive to this combination chemotherapy regimen. Further investigation into whether this combination chemotherapy regimen will be effective against other tumors should be undertaken before recommending its use for breast cancer.